SloveniaSlovenia

Krka wins patent dispute against Pfizer

27.08.2009

Ljubljana – Pharma giants Warner-Lambert and Pfizer have withdrawn their lawsuit against the Slovenian generic manufacturer Krka d.d over the infringement of two patents concerning their US$12bn blockbuster drug Lipitor (atorvastatin), according to a company spokesman. A district court in Ljubljana formally stopped the proceedings related to the alleged infringement of the patents EP 0 839 132 and EP 848 705 on September 19. Previously, the patents that would have expired in 2011, had been finally revoked by the European Patent Office (EPO).
Krka anticipates the planned sales of the product, the company said. In the first half of 2009, the company sales climbed by 2% to EUR 477.8m, generating a net profit of 82.8m over that period.

SloveniaSlovenia

05.03.2010

Ljubljana – Slovenian drugmaker Krka d.d. turned in a solid performance in 2009, with total sales reaching EUR950m, similar to turnover in 2008. Profits rose by around 10% year-on-year to EUR173.7m. The results announced at the...

SloveniaSlovenia

29.04.2009

Ljubljana – BIA Separations d.o.o., the Slovenian specialist for downstream processing of biologicals using monoliths, has received an EUR8m cash injection from the European Investment Bank (EIB). EIB president Philippe Maystadt...

SloveniaSlovenia

21.02.2009

Ljubljana – The most talented young synthetic biologists currently seem to be coming from Eastern Europe. After its success in 2006, a team of young undergraduate chemists from the University of Ljubljana has once again won the...

SloveniaSlovenia

01.11.2008

Belgrade/Lund – Swedish developer of probiotic bacteria Probi AB (Lund) has signed a distribution agreement with Serbian pharmaceutical company Proton System (Belgrade). The agreement gives Proton System the right to sell one of...

SloveniaSlovenia

14.02.2008

Ljubljana/Brussels – Slovenia, which took over the EU presidency from Portugal in January, will put its health-care focus on improving the management of cancer, representatives announced on the presidency website...

Germany, SloveniaSlovenia

24.10.2007

Zagreb – Barr-PLIVA d.d.’s German subsidiary AWD.pharma GmbH & Co. KG. has signed an agreement to acquire O.R.C.A.pharm GmbH (“ORCApharm“), a privately owned specialty pharmaceutical company focused on the oncology market in...

SloveniaSlovenia

17.05.2007

Ljubljana – Slovenia’s national prevention scheme has led to a very low rate of new HIV infections. According to Slovenias’ health minister, Andrej Brucan, fewer than one in 1000 people is infected with the AIDS virus.

SloveniaSlovenia

21.11.2006

Zagreb – Consolidation of the generic-drug business is focusing on eastern Europe. So far in 2006, at least eight deals have been announced, including Barr Pharmaceuticals‘ US$2.5-billion acquisition of Croatia‘s Pliva, completed...

SloveniaSlovenia

21.07.2006

Zagreb – In the bidding race between the Icelandic Actavis Group and US Barr Pharmaceuticals Inc. for the takeover of the Croatian biogenerics producer Pliva d.d., the company ultimately opted for Barr’s offer. Both companies’...

SloveniaSlovenia

17.03.2006

Ljubljana - Lek, the wholly-owned Slovenian subsidiary of Sandoz, Novartis' generics business, will once again cut up to 50 jobs through the course of the year. The redundancies are expected to hit all departments except R&D and...

Displaying results 1 to 10 out of 22

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-slovenia/article/krka-wins-patent-dispute-against-pfizer.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THROMBOGENICS (B)9.54 EUR-5.07%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.77 EUR-29.2%
  • PROSENSA (NL)9.81 USD-22.6%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products